Dossier assessment

Ingenol mebutate (actinic keratosis) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A18-55
Last updated

Report documents

  1. Extract of dossier assessment

    Ingenol mebutate (actinic keratosis) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 92 kB, EN, not accessible
  2. Dossier assessment

    Ingenol mebutate (actinic keratosis) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 465 kB, DE, not accessible

Dossier assessment

Indication:

Patients with non-hyperkeratotic, non-hypertrophic actinic keratosis

Result of dossier assessment:

Actinic keratosis on face or scalp: hint of non-quantifiable (at most considerable) added benefit; on trunk or extremeties: added benefit not proven

Press releases

AMNOG as a learning system: New study on ingenol mebutate in actinic keratosis shows added benefit

Advantage over diclofenac in complete clearance of visible lesions / unclear sustainability of treatment effect

Additional information

Federal Joint Committee (G-BA)

20 August 2020: The G-BA’s decision of 21 February 2019 was cancelled.
G-BA documents on this decision

Project details

Project no.
A18-55
Commission
Commission awarded on 03.09.2018 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Skin and hair
Note

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Connected Projects

  1. Addendum

    Ingenol mebutate (actinic keratosis) - Addendum to Commission A18-55

    Project no.
    A19-02
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Ingenol mebutate - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

    Project no.
    A13-04
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form